Latest New Zealand News

City Chic Collective reports a robust 71% rise in underlying EBITDA for the first half of FY26, powered by strong ANZ revenue growth and strategic inventory management in the US despite tariff headwinds.

Wellnex Life reports a $2.4 million EBITDA improvement in H1 FY26 and reaches breakeven by Q2, supported by strong Pain Away sales and expanded distribution.

Channel Infrastructure has reported a 3.9% increase in fuel throughput for Q4 2025, marking its highest quarterly volume since import terminal operations began. Key infrastructure projects are progressing ahead of schedule, positioning the company strongly for future growth.

BlueScope announces a $1.00 per share unfranked special dividend, returning $438 million to shareholders from recent asset sales and working capital releases. The steelmaker signals a robust cash flow outlook with a planned capex reduction in FY2027.

Fletcher Building’s Q2 FY26 volumes edged up modestly from the previous quarter, buoyed by gains in light building products, while heavy materials continued to decline amid ongoing margin pressures.

Domino’s Pizza Enterprises has appointed Merrill Pereyra as CEO for Australia and New Zealand, while expanding George Saoud’s responsibilities to include Chief Operating Officer. These leadership moves aim to accelerate the company’s turnaround and operational efficiency.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its Vision-MR Diagnostic Catheter, paving the way for commercial sales in the US electrophysiology market.

Kalamazoo Resources has initiated a $2 million underwritten Share Purchase Plan, offering eligible shareholders shares at a 16.4% discount to recent prices. The offer aims to fund exploration and development activities across its Victorian and Western Australian projects.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

BlueScope Steel’s board has unanimously dismissed a $30 per share takeover proposal from SGH and Steel Dynamics, calling it opportunistic and undervaluing the company’s assets and growth prospects.